"Lymphoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A general term for various neoplastic diseases of the lymphoid tissue.
Descriptor ID |
D008223
|
MeSH Number(s) |
C04.557.386 C15.604.515.569 C20.683.515.761
|
Concept/Terms |
Lymphoma- Lymphoma
- Lymphomas
- Sarcoma, Germinoblastic
- Germinoblastic Sarcoma
- Germinoblastic Sarcomas
- Sarcomas, Germinoblastic
- Reticulolymphosarcoma
- Reticulolymphosarcomas
- Germinoblastoma
- Germinoblastomas
- Lymphoma, Malignant
- Lymphomas, Malignant
- Malignant Lymphoma
- Malignant Lymphomas
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma".
Below are MeSH descriptors whose meaning is more specific than "Lymphoma".
This graph shows the total number of publications written about "Lymphoma" by people in this website by year, and whether "Lymphoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1993 | 4 | 2 | 6 |
1994 | 1 | 1 | 2 |
1995 | 1 | 0 | 1 |
1996 | 4 | 2 | 6 |
1997 | 1 | 0 | 1 |
1998 | 5 | 1 | 6 |
1999 | 5 | 3 | 8 |
2000 | 6 | 1 | 7 |
2001 | 2 | 0 | 2 |
2002 | 2 | 1 | 3 |
2003 | 6 | 4 | 10 |
2004 | 5 | 3 | 8 |
2005 | 3 | 3 | 6 |
2006 | 2 | 3 | 5 |
2007 | 1 | 1 | 2 |
2008 | 3 | 1 | 4 |
2009 | 4 | 2 | 6 |
2010 | 11 | 1 | 12 |
2011 | 7 | 1 | 8 |
2012 | 3 | 1 | 4 |
2013 | 2 | 2 | 4 |
2014 | 3 | 0 | 3 |
2015 | 3 | 1 | 4 |
2016 | 2 | 1 | 3 |
2017 | 6 | 0 | 6 |
2018 | 2 | 2 | 4 |
2019 | 1 | 0 | 1 |
2020 | 2 | 0 | 2 |
2021 | 3 | 1 | 4 |
2022 | 4 | 0 | 4 |
2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphoma" by people in Profiles.
-
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study. Clin Cancer Res. 2023 01 04; 29(1):110-121.
-
Advances in the Classification of Myeloid and Lymphoid Neoplasms. Virchows Arch. 2023 01; 482(1):1-9.
-
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022 07; 36(7):1720-1748.
-
Exome sequencing identifies PD-L2 as a potential predisposition gene for lymphoma. Hematol Oncol. 2022 Aug; 40(3):475-478.
-
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2022 02 15; 28(4):677-688.
-
Leukemic and Lymphomatous Optic Neuropathy: A Case Series. J Neuroophthalmol. 2021 Dec 01; 41(4):e796-e802.
-
Negative innovation: when patents are bad for patients. Nat Biotechnol. 2021 08; 39(8):914-916.
-
First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas. J Immunother Cancer. 2021 08; 9(8).
-
Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma. Leuk Lymphoma. 2021 07; 62(7):1629-1638.
-
Combined EBUS-IFB and EBUS-TBNA vs EBUS-TBNA Alone for Intrathoracic Adenopathy: A Meta-Analysis. Ann Thorac Surg. 2022 07; 114(1):340-348.